Alexion Pharmaceuticals Inc (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2008

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Alexion Pharmaceuticals, Inc.
Ticker: ALXN CIK: 899866

Exhibit 99.1

LOGO

Alexion Reports Fourth Quarter and Full Year 2008 Results

— $259 Million in Soliris® Sales in First Full Commercial Year —

— Continued Strong Uptake of Soliris in U.S. and Europe in Q4 —

— Soliris Research Programs Progress: Clinical Data in PNH and Other

Rare Diseases Presented at ASH and ASN —

2008 and Fourth Quarter Financial Highlights:

•

Total 2008 Soliris® (eculizumab) net product sales were $259.0 million, compared to $66.4 million in 2007.

•

Soliris net product sales were $77.4 million in Q4 2008, reflecting a strong addition of new patients during the quarter, compared to $33.9 million in Q4 2007.

•

Soliris net product sales in Q4 2008 increased nine percent compared to Q3 2008 net product sales of $71.2 million for shipments that occurred in Q3, despite a negative impact from foreign exchange. Q3 2008 net product sales additionally included recognition of a further $5.3 million for Soliris shipments that occurred in previous quarters.

•

2008 GAAP net income was $33.1 million, or $0.39 per diluted share, compared to a GAAP net loss of $92.3 million, or $1.27 per share, in 2007.

•

2008 non-GAAP net income was $56.8 million, or $0.64 per diluted share, compared to a non-GAAP net loss of $72.1 million, or a net loss of $0.99 per share, in 2007.

•

Q4 GAAP net income was $15.3 million, or $0.17 per diluted share, compared to a GAAP net loss of $12.3 million, or $0.17 per share, in Q4 2007.

•

Q4 non-GAAP net income was $21.1 million, or $0.23 per diluted share, compared to a non-GAAP net loss of $8.5 million, or $0.11 per share, in Q4 2007.

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 12, 2009 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Alexion Pharmaceuticals, Inc.

Makovsky & Company

Rx Communications

Irving Adler

Kristie Kuhl (Media)

Rhonda Chiger (Investors)

Sr. Director, Corporate

Communications

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Alexion Pharmaceuticals, Inc..

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/899866/000119312509035223/d10k.htm